Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Disease Management Will Yield More Savings In Medicare Than Private Plans, CMS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Medicare beneficiaries offer a more stable population with a greater number of chronic diseases than those in private plans, CMS’ Guterman says. Current expectations about possible returns on investment from disease management programs are too high, Disease Management Purchasing Consortium says.

You may also be interested in...



Employer Enthusiasm For Disease Management Is Waning, Insurers Say

PBMI Prescription Drug Utilization Conference attendees express caution about the motives of pharmaceutical manufacturer-sponsored disease management programs. Preliminary results from PBMI’s 2005 benefit design report found that a lower percentage of employers are using disease management programs.

Medicare Chronic Disease Management Pilots To Begin In Spring 2005

HHS selects nine organizations to coordinate care for 180,000 Medicare beneficiaries with congestive heart failure, complex diabetes and chronic obstructive pulmonary disease. The programs will be evaluated through randomized controlled trials.

Disease Management Program Cost Savings Not Yet Demonstrated, CBO Says

While studies show such programs improve control of diseases, the net effect on health costs is not clear, a Congressional Budget Office report says. Translating successful disease management results to the Medicare population could be difficult, the report notes.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel